A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder (ADHD) prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before…
Ionis Pharmaceuticals has offloaded regional rights to its near-approval rare disease asset zilganersen, pocketing $30 million upfront from Recordati for an…
Natural hallucinogens—psychoactive compounds such as psilocybin, mescaline, and N,N-dimethyltryptamine (DMT)—have long captured human fascination due to their profound effects on…
In a groundbreaking study published in Nature Communications, researchers have unveiled a comprehensive comparative genomic analysis of fungi intimately associated…